← 產業報告目錄

Fibroblast Growth Factor Receptor 2 Inhibitor Market, By Drug (Pemigatinib, Futibatinib, Tasurgratinib, Tinengotinib, and Lirafugratinib), By Indication (Cholangiocarcinoma, Gastric Cancer, Endometrial Cancer, and Others), By End User (Hospitals, Specialty Clinics, Cancer Centers, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

出版商 Coherent Market Insights出版日期 2026-07-02頁數 255報告編號 CMR-540c96b65b

授權報價

Single User Price$4,500 USD
Site License Price$7,000 USD
Enterprisewide Price (Global Site License)$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global fibroblast growth factor receptor 2 inhibitor market is estimated to be valued at USD 196.3 Mn in 2026 and is expected to reach USD 554.0 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 16.0% from 2026 to 2033. Fibroblast growth factor receptor 2 (FGFR2) inhibitors are targeted therapeutic drugs that are a part of a group of medications to halt unusual FGFR2 signaling through various factors including genetic fusions, mutations, and amplification in diseases such as gastric and uterine cancer, breast cancer, intrahepatic cholangiocarcinoma. This treatment strategy targeting signaling pathways that regulate proliferation, survival of cancer cells and angiogenesis has evolved as a crucial treatment regimen in the precision oncology sector. The global fibroblast growth factor receptor 2 inhibitor market will gain momentum due to rising trends for cancer treatment focused on biomarkers, growing utilization of genome profiling technologies and heightened knowledge of FGFR2-based tumor biological processes. Moreover, the number of approvals and designations granted to specific FGFR inhibitors coupled with ongoing development of diagnostics paired along with companion tests has a capacity to identify eligible population for FGFR2-targeted drugs and aids market augmentation. FGFR2 inhibitor treatment also continues to gain traction across developed and developing markets. Market Dynamics The global fibroblast growth factor receptor 2 inhibitor market is driven by increasing incidences of FGFR2-altered cancers, especially cholangiocarcinoma. Moreover, the increasing prescription rates of genomic profiling and companion diagnostics to accurately determine the eligibility of patients for the utilization of FGFR2-targeted agents and regulatory approvals. Additionally, pipeline progress associated with the next-generation selective FGFR2 inhibitors are expected to play a critical role in propelling the market. Also, strategic partnerships among pharmaceutical organizations, biotechnology companies and research institutions will further strengthen the pace of the FGFR2 inhibitors pipeline. However, a number of constraints are present in the market, such as prohibitively expensive nature of targeted therapies, lack of adequate reimbursement facilities across numerous regions, and limited patient pool affected by FGFR2 alterations. Nevertheless, extensive pipeline progress focused on next-generation FGFR2 inhibitors, application of combinatorial therapy and increase in reach of molecular diagnostics in developing markets will offer new opportunities for growth in fibroblast growth factor receptor 2 inhibitor market. Key Features of the Study • This report provides in-depth analysis of the global fibroblast growth factor receptor 2 inhibitor market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global fibroblast growth factor receptor 2 inhibitor market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include Incyte Corporation, Taiho Pharmaceutical Co., Ltd., Relay Therapeutics, Inc., Janssen Pharmaceuticals, BridgeBio Pharma, Inc., Tyra Biosciences, Inc., Abbisko Therapeutics Co., Ltd., AstraZeneca PLC, Kinnate Biopharma Inc., and Novartis AG • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global fibroblast growth factor receptor 2 inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fibroblast growth factor receptor 2 inhibitor market Market Segmentation • Drug Insights (Revenue, USD Mn, 2021 - 2033) o Pemigatinib o Futibatinib o Tasurgratinib o Tinengotinib o Lirafugratinib • Indication Insights (Revenue, USD Mn, 2021 - 2033) o Cholangiocarcinoma o Gastric Cancer o Endometrial Cancer o Others • End User Insights (Revenue, USD Mn, 2021 - 2033) o Hospitals o Specialty Clinics o Cancer Centers o Others • Regional Insights (Revenue, USD Mn, 2021 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o Incyte Corporation o Taiho Pharmaceutical Co., Ltd. o Relay Therapeutics, Inc. o Janssen Pharmaceuticals o BridgeBio Pharma, Inc. o Tyra Biosciences, Inc. o Abbisko Therapeutics Co., Ltd. o AstraZeneca PLC o Kinnate Biopharma Inc. o Novartis AG
目錄 Table of Contents
Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By Drug  Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By Indication  Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By End User  Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By Region 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Impact Analysis o Key Highlights o Regulatory Scenario o Product Launches/Approvals o PEST Analysis o PORTER’s Analysis o Market Opportunities o Regulatory Scenario o Industry Trends 4. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By Drug, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Pemigatinib  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Futibatinib  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Tasurgratinib  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Tinengotinib  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Lirafugratinib  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 5. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By Indication, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Cholangiocarcinoma  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Gastric Cancer  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Endometrial Cancer  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 6. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By End User, 2021-2033, (USD Mn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Hospitals  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Specialty Clinics  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Cancer Centers  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn) 7. Global Fibroblast Growth Factor Receptor 2 Inhibitor Market, By Region, 2021 - 2033, Value (USD Mn) o Introduction  Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)  Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)  Regional Trends o North America  Introduction  Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o Brazil o Argentina o Mexico o Rest of Latin America o Europe  Introduction  Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o Germany o U.K. o Spain o France o Italy o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o China o India o Japan o Australia o South Korea o ASEAN o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn) o GCC Countries o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, By Drug, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)  Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn) o South Africa o North Africa o Central Africa 8. Competitive Landscape o Incyte Corporation  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Taiho Pharmaceutical Co., Ltd.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Relay Therapeutics, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Janssen Pharmaceuticals  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o BridgeBio Pharma, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Tyra Biosciences, Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Abbisko Therapeutics Co., Ltd.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o AstraZeneca PLC  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Kinnate Biopharma Inc.  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies o Novartis AG  Company Highlights  Product Portfolio  Key Developments  Financial Performance  Strategies 9. Analyst Recommendations o Wheel of Fortune o Analyst View o Coherent Opportunity Map 10. References and Research Methodology o References o Research Methodology o About us Browse 32 market data tables and 28 figures on ‘Fibroblast Growth Factor Receptor 2 Inhibitor Market' - Global forecast to 2033
圖表清單 List of Tables & Figures
NA NA

提及公司

o Incyte Corporationo Taiho Pharmaceutical Co.Ltd.o Relay TherapeuticsInc.o Janssen Pharmaceuticalso BridgeBio PharmaInc.o Tyra BiosciencesInc.o Abbisko Therapeutics Co.Ltd.o AstraZeneca PLCo Kinnate Biopharma Inc.o Novartis AG

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們